Cardiology 2013

ISSN: 1522-9645 (Electronic)

0195-668X (Linking)

Accession Number: 24083306

Abstract: Dr David Erlinge, the Society President, outlines the history and present-day activities of the Society.

Notes: Erlinge, David

eng

News

England

2013/10/02 06:00

Eur Heart J. 2013 Aug;34(30):2336.

URL: http://www.ncbi.nlm.nih.gov/pubmed/24083306

 

 

Reference Type:  Journal Article

Record Number: 765Author: Eschenhagen, T. and Blankenberg, S.

Year: 2013

Title: [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]

Journal: Internist (Berl)

Volume: 54

Issue: 2

Pages: 147-8, 150-2, 154

Date: Feb

Short Title: [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases]

Alternate Journal: Der Internist

ISSN: 1432-1289 (Electronic)

0020-9554 (Linking)

DOI: 10.1007/s00108-012-3157-8

Original Publication: Personalisierte Therapie in der Kardiologie. Biomarker, Pharmakogenetik und Therapie monogener Erkrankungen.

Accession Number: 23371262

Keywords: Biological Markers/analysis

Cardiology/*trends

*Cardiovascular Diseases/diagnosis/genetics/therapy

Genetic Markers/*genetics

Genetic Testing/*methods

Genetic Therapy/*trends

Humans

Individualized Medicine/*methods

Molecular Targeted Therapy/*trends

Pharmacogenetics/trends

Abstract: Improved therapy and prophylaxis of cardiovascular diseases have contributed to an increase in life expectancy like no other field of medicine. However, many cardiological diseases remain untreatable and standard therapies often work only in a minority of patients or cause more harm than benefit. Personalized approaches appear to be a promising solution. Monogenic heart diseases are paradigmatic for this approach and can in rare cases be treated mutation specifically. Overall, however, success remains limited. Next generation sequencing will facilitate the identification of mutations causing diseases. Cell culture models based on induced pluripotent stem cells open the perspective of individualized testing of disease severity and pharmacological or genetic therapy. In contrast to monogenic diseases genetic testing plays no practical role yet in the management of multifactorial cardiovascular diseases. Biomarkers can identify individuals with increased cardiovascular risk. Furthermore, biomarker-guided therapy represents an attractive option with troponin-guided therapy of acute coronary syndromes as a successful example. Individual responses to drugs vary and are partly determined by genes. Simple genetic analyses can improve response prediction and minimize side effects in cases such as warfarin and high doses of simvastatin. Taken together personalized approaches will gain importance in the cardiovascular field but this requires the development of better methods and research that quantifies the true value of the new knowledge.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208